Potential source of financing/partnership
|For information only|
|Solicitation HHS-NIH-NIAID-BAA2020-1||April 9, 2020|
Research Area 003: Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases
Research Area 004 - Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases
Research Area 005 - Advanced Development of Diagnostics for Biothreats and Emerging Infectious Diseases
|3 or more awards across Research Area 003 and 004 for a total cost of up to $11.5 million for the non-severable base work across all contracts (direct and indirect costs combined). The total performance period proposed should not exceed five (5) years.|
1 or more awards across Research Area 003 and 004 for a total cost of up to $2 million for the non-severable base work across all contracts (direct and indirect costs combined). The total performance period proposed should not exceed five (5) years.
|BARDA (Biomedical Advanced Research and Development Authority)||Solicitation BAA-18-100-SOL-00003||2020, April 30||COVID-19-related funding. Areas of interest include:|
7.7 Emerging Diseases Diagnostics
7.7.1 Diagnostic Assay for human coronaviruses using existing FDA-cleared
7.7.2 Point-of-Care Diagnostic Assay for detection of SARS-CoV-2 virus
7.7.3 Diagnostic Assay for detection of COVID-19 disease (SARS-CoV-2 infection)
9.2 COVID-19 Therapeutics
9.3 Immunomodulators or therapeutics targeting lung repair
9.4 Innovative approaches to improve clinical trial execution for hospitalized
9.5 Pre-exposure and Post-exposure Prophylaxis
Quad Chart/White Paper (Stage 1)
Full Proposal (Stage 2)
|NIH/NIAID||RFA-AI-20-028 Partnerships for Countermeasures against Select Pathogens||LOI due May 20, Grant due June 29||RFA-AI-20-028 (R01 Clinical Trials Not Allowed)|
This FOA solicits research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens. Applications must include a Product Development Strategy attachment and demonstrate substantive investment by at least one industrial participant.
|Recommended budget for direct costs of up to $750,000 per year may be requested. Applicants may also request up to an additional $300,000 in the first year of the award for major equipment to ensure that research objectives can be met and biohazards can be contained, totaling $1,050,000 direct costs for Year 1 only.|
National Heart, Lung, and Blood Institute (NHLBI)
|Notice of Special Interest (NOSI) NOT-HL-20-757 issued by NHLBI||Depending on parent award||Supplements of existing grants. Possible research interests include but are not limited to the following:|
Host factors, including the microbiome or existing cardiac, respiratory, or hematologic conditions, that predispose persons to acquire SARS-CoV-2 or to develop severe COVID-19 disease, or that confer resistance to severe disease as in infants and young children
Manifestations, complications, and long-term consequences of SARS-CoV-2 infection, including identification of predictive biomarkers derived from imaging, clinical data, and biospecimens collected across organ systems
Time course and features of virus-host interactions, including the impact of SARS-CoV-2 infection on innate and adaptive immune responses
Prevalence and mechanisms of lung and cardiac injury with SARS-CoV-2 infection
Host factors and biological pathways that impact recovery and repair of the cardiopulmonary and vascular systems after SARS-CoV-2 infection
Development of animal or in vitro models of SARS-CoV-2 infection suitable for pathogenesis and therapeutic studies or transfusion transmission experiments such as, but not limited to, macaque and ACE-2 receptor murine models
Use of artificial intelligence or machine learning approaches to understand the biological pathways of COVID-19 disease, its comorbidities, and potential prevention strategies
Prevalence of RNAemia in symptomatic and asymptomatic people found to test positive for SARS-CoV-2 using respiratory tract samples
Dynamics of SARS-CoV-2 viremia and antibody response, and implications on screening and diagnostic assay development
Development of GMP quality hyper immune globulin from convalescent plasma collected from patients who have recovered from documented SARS-CoV-2 infection
Development and testing of strategies at the healthcare system level to address barriers and facilitators in the treatment of high-risk populations, particularly rural residents and underserved individuals
Supplementary funds may be used for the collection of blood or lung samples from human cohorts of individuals with COVID-19 or evidence of SARS-CoV-2 infection or controls, and/or development of novel model systems to expose animals and cells to SARS-CoV-2.
|Up to parent grant||NOSI specific for PA-18-591 (supplements)|
Eligible activity codes are limited to the mechanisms (see link) + Application must have sufficient time left to complete the studies proposed after the supplement or revision has been awarded within the existing project period.
National Institute of Allergy and Infectious Diseases (NIAID)
|Notice of Special Interest (NOSI) NOT-AI-20-034 issued by NIAID||Rolling||Revisions of existing grants. Possible research interests include but are not limited to the following:|
• Dev of reagents and assays for virus characterization;
• Studies to understand critical aspects of viral infection, replication, pathogenesis, and transmission;
• Studies to identify viral epitopes critical for binding neutralization;
• Production of molecular clones of 2019-nCoV, reporter viruses and recombinant viral proteins;
• Dev of sensitive, specific, and rapid clinical diagnostic tests for 2019-nCoV;
• Dev of 2019-nCoV therapeutic candidates; broad-spectrum therapeutics against multiple coronavirus strains; examination of 2019-nCoV antiviral activity of existing or candidate therapeutics initially developed for other indications;
|Depending on parent grant||Apply through PA-20-135 mechanism (previously: NOSI specific for PA-18-935 (revisions). Eligible activity codes are limited to the following mechanisms: P01, R00, R01, R03, R15, R21, R33, R35, R41, R42, R43, R44, R61, U01, U24, U54, UG3, UH3, UM1)|
Wellcome, Mastercard Foundation
|COVID-19 Therapeutics Accelerator||Treatment. |
Accelerating and evaluating new and repurposed drugs and biologics to treat patients.
|National Institute of General Medical Sciences (NIGMS)||Notice of Special Interest (NOSI) NOT-GM-20-025 issued by NIGMS||Rolling||NIGMS will accept the submission of applications for Competitive Revisions to active grants to address only the following research areas of interest:|
1. Incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants).
Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection (SBIR/STTR grants only).
2. Rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR only).
|Depending on parent grant||Applications in response to this NOSI must be submitted to PA-18-935 "Urgent Competitive Revision to Existing NIH Grants|
|NSF||NSF 20-052||non-medical, non-clinical-care research that can be used immediately to explore how|
to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge
Proposals in response to this DCL may also request the use of NSF-funded advanced
computing resources such as Frontera, Stampede2, Bridges, Comet, and JetStream.
|up to $200K and up|
to one year in duration
|Through existing NSF funding opportunities|
|AFWERX (US Air Force)||Information collection of needs and solutions||1. Combating the Spread (predictive analytics, next hotspot, threat to current activities, decision support, etc.)|
2. Welfare of citizens (effects to transportation, movement of people and goods, education and development, physical training, regular HR functions, job transition, etc.)
3. Readiness (continuing operations through the outbreak, coordinating with allies and partners, continuing long term projects, etc.)
4. Logistics (security and protection, supply chain protection and assessment, etc.)
5. Industrial base impacts (small businesses, payments, contracts, large system programs, protection and expansion of critical assets, etc.)
6. Medical (telehealth, medical capacity and sustainment, medical supplies and equipment, etc.)
|Non-govermental and governmental solutions accepted|
|Consortium established by C3.ai and Microsoft, and led by UCB, UIUC,|
Carnegie Mellon University, University of Chicago, MIT, and Princeton University
|Call for Proposals||5/1/2020 but better by April 15||The Institute catalyzes cooperative research activities to accelerate advances in research, combining machine learning (ML), artificial intelligence (AI), the internet of things (IoT), management science, ethics, and public policy to transform and enhance the quality of life in societal systems at large.|
Looking for bold proposals -- ethical questions, tech questions, diagnostics/therapeutics -- leveraging C3 platform.
- Modeling, analysis, of the spread
- Strenghen public health systems
- Minimize the spread
Costas Spanos from UCB is C3.ai DTI Chief Scientist.
|Private fund from $100k (8), $250k (16) to $500k (2), use of the C3 AI software suite, and a significant amount of Microsoft Azure cloud computing time and scientific computing time as needed on NCSA/LBNL supercomputers|
Project needs to be completed within a year
Favors projects using C3's computing platform
Prefer outcomes to be made pubicly available immediately.
No applications limit per PI
|Agency for Healthcare Research and Quality (AHRQ)||Notice of Intent NOT-HS-20-007||TBD||New funding notice allowing requests for urgent revision supplements to existing AHRQ grants to address health system responsiveness to COVID-19.||Depending on parent grant|
Grant activity codes to be included or excluded from the funding notice will specified in the announcement.
|Agency for Healthcare Research and Quality (AHRQ)||Notice of Intent NOT-HS-20-008||AHRQ is working to publish the FOA in early May 2020 with submissions due in June 2020.||New funding opportunity announcement using the R01 mechanism to support novel, high-impact studies evaluating health system and healthcare professional responsiveness to COVID-19. |
Funds critical research focused on innovations and challenges encountered in the rapid expansion of telemedicine in response to COVID-19, effects on quality, safety, and value of health system response to COVID-19, and the role of primary care practices and professionals during the COVID-19 epidemic. AHRQ is particularly interested in understanding how digital health innovations contributed to health system and healthcare professional innovation and challenges and solutions to meeting the needs of vulnerable populations including older adults, people living with multiple chronic conditions, rural communities, and uninsured and underinsured populations.
|AHRQ expects to invest up to $5M in FY2020 funds to support this initiative and potentially more pending supplemental funding.|
AHRQ will encourage multimethod, rapid-cycle research with the ability to produce and disseminate findings as early as 6 months.
|The Schmidt Futures Tech + COVID19 group||Pre-read document where you can describe what you are doing and what you need||Next all-hands call will be on April 7||A listserv for interested parties to flag two types of information: (a) requests for help (partners for emerging areas of interest; co-funding), (b) an offer of help (talent; funding; network), for others in the group. They would like to form 3-5 rapid-action working groups. Some possible topics (ventilators/supply shortages; rapid testing and tracing). They will circulate more information on the first set of rapid-action working groups shortly on the listserv.||Ask for being added to the listserv|
|NASEM (George Strawn), ORFG (Open Research Funders Network that HHMI belongs to) and GO FAIR VODAN (Barend Mons)||The GO FAIR Virus Outbreak Data Network (VODAN)||They need subject specific experts (for example, virologists, epidemiologists, etc) who could vet/certify/review/annotate COVID19-related preprints. They need engineers to develop FAIR data repositories (FAIR data points) with ‘docking’ capabilities as a ‘station’ for ‘trains’ (virtual machines (VMs)) that come to ‘visit’ the data locally, with a specific question to ask. They need data scientists to interrogate the databases the network is linking out to. The databases include sequences of COVID19 variants, possible drug targets, clinical data and patient outcomes (in the form of electronic Clinical Research Forms (CRFs)) from across the globe.||Those interested should sign up on the VODAN site (Contact form) to become an active participant and contributor. Others could be observers.|
|Consortium||High Performance Computing Consortium||The Consortium is a unique private-public effort spearheaded by the White House Office of Science and Technology Policy, the U.S. Department of Energy and IBM to bring together federal government, industry, and academic leaders who are volunteering free compute time and resources on their world-class machines. Researchers are invited to submit COVID-19 related research proposals to the consortium.||Access to computing resources||a description, no longer than two pages, of your proposed work|
|NCATS||Notice of Special Interest (NOSI) NOT-TR-20-011: Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need||May 4, 2020 for PA-18-591 mechanism (UL1, U01, R21 activity codes)|
Later for others
|Use of informatics solutions to diagnose cases and the use of CTSA-supported core resources (e.g., advanced scientific instruments, highly-specialized facilities, and regulatory expertise) to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines. NCATS is soliciting applications for Administrative Supplements to UL1, U01, and R21 awards (through PA-18-591), Collaborative Innovation Awards to U01 and R21 awards (through PAR-19-099 and PAR-19-100, respectively), and Competitive Revisions for UL1 awards for each of the non-administrative supplement awards (through PAR-19-337).||Depending on parent grant|
|CDC||Contract: Call for white papers||2020, March 25||Notice 75D301-20-R-67897|
#1: Surveillance, natural history and household transmission of SARS CoV-2
#2: Diagnostics development and novel technology development and evaluation to improve diagnostic testing capabilities for COVID-19 detection
#3: Immune response and transmission dynamics for SARS CoV-2
#4: Host infection dynamics for SARS CoV-2
#5: Prospective Cohorts to Assess COVID-19 and Other Respiratory Diseases
Each white paper must adhere to all of the following requirements and should be no more than 4 pages in
length per subtopic area. The email subject line for the white paper shall include research topic number
and subtopic title.
• White Paper must be written in the following format:
a. Font size: 12-point, unreduced
c. Paper size: 8.5 by 11 inches
d. Page Margin Size: One inch
e. Printed only on one side of page
f. Descriptive Title of the Proposed Project
g. BAA Number
• White paper submissions shall be unclassified.
• Project description addressing in sufficient detail the characteristics identified in Part II. The offeror
may submit an individual white paper for any or all of the topic areas under Part II.
• Point of contact.
• A rough order of magnitude (ROM) cost estimate to implement the research effort.
• An estimated timeline to complete the project.
|Medical CBRN Defense Consortium (MCDC) + Department of Defense’s (DoD)||Solicitation||2020, March 21 (recommended)|
Open until 2020, May 31
|White Papers with a focus on the following areas:|
Diagnostics/Monitoring: Medical diagnostic devices, with specific emphasis on Point-of-Care diagnostics (e.g. CLIA waived), under development and capable of diagnosing 2019- SARS-CoV-2, and achieving Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA) within the next one to four (1-4) months.
Surveillance: Surveillance methods and associated devices for 2019-SARS-CoV-2 screening. Any technology that can enhance the understanding of disease progression in COVID-19 infected patients is also of interest, including physiologic monitoring and other vital signs indicators, portable technology that enhances patient care in non-hospital settings, and technology that improves sample collection.
|Medical CBRN Defense Consortium (MCDC) + Department of Defense’s (DoD)||Solicitation (no specific link yet)||2020, March 27||RPP-20-04|
Advance Treatment Based on Polyclonal Antibodies to Treat Coronavirus Disease 2019 (COVID-19) Response
|Amazon||Amazon’s Disaster Relief||Provides financial credits on the AWS cloud to help your research respond quickly to this critical community crisis|
|CDC||Supplemental funding CDC-RFA-OT18-18020202SUPP20||April 2, 2020||Only available to organizations that received funding under Funding Strategy 1 of CDC-RFA-OT18-1802: "Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health" in 2018.||$1M|
|PAR-20-139 Investigator Initiated Extended Clinical Trial||May 13, 2020 then September 13, 2020||R01 Clinical Trial Required|
This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated clinical trials requiring an extended project period of 6 or 7 years. The trials can be any phase, must be hypothesis-driven, and related to the research mission of one of the participating ICs.
Small Business Innovation Research (SBIR)
|Small Business Innovation Research Program Phase I (SBIR)|
Program solicitation NSF 20-527
|NEXT submission window for Project Pitch closes JUNE 4, 2020||Support research and development (R&D) of unproven, high-impact innovations, and development of deep technologies, based on discoveries in fundamental science and engineering for profound societal impacts|
Phase I: 3-page project pitch
Phase II: full application
|Phase I: up to $256k|
Phase II: up to $1M
Small Business Technology Transfer (STTR)
|Small Business Technology Transfer Program Phase I (STTR)|
|NEXT submission window for Project Pitch closes JUNE 4, 2020||The NSF STTR program focuses on transforming scientific discovery into products and services with commercial potential and/or societal benefit. Unlike fundamental research, the NSF STTR program supports startups and small businesses in the creation of deep technologies, getting discoveries out of the lab and into the market.|
The NSF STTR Program funds research and development. The program is designed to provide non-dilutive funding and entrepreneurial support at the earliest stages of company and technology development.
|Phase I: up to $256k|
Phase II: up to $1M
The Division of Innovation and Industrial Partnerships (IIP) of the Engineering Directorate
|Request for SBIR/STTR Phase I Proposals Addressing COVID-19|
|Areas of research that might be considered include, but are not limited to: artificial intelligence, digital health, diagnostics, distributed ledger, environmental technologies, medical devices, pharmaceutical technologies, disinfection and sterilization, and filtration and separations.|
|Medical Technology Enterprise Consortium||MTEC-Presolicitation-COVID-19||April 15||Potential areas of interest:|
Point-of-care diagnostic that provides rapid and accurate determination on exposure to COVID-19.
Prophylactic(s)/Therapeutic(s) that can prevent and/or treat in a rapid manner (few hours to 2 days) potentially in a non-hospital environment. Repurposing FDA-approved drugs/biologics for prevention/treatment of COVID-19 or testing of drugs/biologics that have already demonstrated safety in humans for the prevention/treatment of COVID-19 are preferred.
Disease predictive modeling that provides early warning through data capture from several different streams of data to include social media and artificial intelligence (AI) parameter decision tools that would provide actionable information to medical service providers and command structures.
Patient monitoring, tracking, and management system for in-home or non-hospital environment patient tele-health services to include interface into the Cerner electronic health record.
|MTEC believes that an emphasis will be placed on technologies that can be deployed as soon as possible but no later than 31 December 2020.|
Computational and Data-Enabled Science and Engineering (CDS&E) or Cyberinfrastructure for Sustained Scientific Innovation (CSSI) programs
|NSF 20-055 Provisioning Advanced Cyberinfrastructure to Further Research on COVID-19||Complements NSF 20-052 |
RAPID proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities.
Proposals in response to this DCL and the NSF DCL on COVID-19 (NSF 20-052) may also request the use of NSF-funded advanced computing resources such as Frontera, Stampede2, Bridges, Comet, and JetStream.
|BARDA (Biomedical Advanced Research and Development Authority)||BAA-20-100-SOL-0002, EZ BAA application process for diagnostics||March 18, 2020||Focus area AOI #4: 2019-nCoV: development and Emergency Use Authorization (EUA) of an in vitro diagnostic assay for the detection of 2019-nCoV RNA in clinical specimens, including upper (e.g, nasopharyngeal and oropharyngeal swabs, nasopharyngeal wash/aspirate, or nasal aspirate) and lower (e.g., bronchoalveolar lavage, tracheal aspirate, or sputum) respiratory tract specimens.||Up to $749k||Abstract. Viable plan that achieves an EUA submission milestone within 12 weeks of award. Describe the current development status of your 2019-nCoV assay, including in silico analysis of targets, access to validation materials to support EUA submission, and contacts with the FDA.|
|BARDA (Biomedical Advanced Research and Development Authority)||Portal: request a CoronaWatch meeting before submitting any application + apply online||April 30||COVID-19 response related Areas of Interest includes:|
7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms
7.7.2 Point-of-care diagnostic assay for detection of SARS-CoV-2 virus
AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection)
AOI 8.3 COVID-19 Vaccine
AOI 9.2 COVID-19 Therapeutics
AOI 9.3 Immunomodulators or therapeutics targeting lung repair
AOI 9.5 Pre-exposure and post-exposure prophylaxis
AOI 10 Respiratory protective devices
AOI 11 Ventilators
AOI 17 Advanced Manufacturing Technologies
|Department of Energy (DOE)||Leveraging DOE user facilities, computational resources, enabling infrastructure||Rolling||Research questions|
|Chan Zuckerberg Initiative (CZI) and Chan Zuckerberg Biohub|
UCSF and Stanford University
|COVID-19 Task Force||Quadruple the Bay Area’s COVID-19 testing and diagnostics capacities||Funding acquisition of 2 state-of-the-the-art FDA approved clinical diagnostic machines|
Increase UCSF's capabilties to diagnose
|Ginkgo Bioworks||Access to platform||Funding towards projects that can use Ginkgo’s platform to accelerate development of point of care diagnostics, vaccines, or therapeutics.|
Connection to sources of funding from private and public sources
|$25M of no-cost foundry work|
|Natural Hazards Center||Quick Response Research Grant Program||April 1, 2020||maximum five-page proposal (not including references) |
Provides funds and training for eligible researchers to collect data in the aftermath of extreme events to document disaster before memories fade and physical evidence is erased.
How COVID-19 is affecting potentially vulnerable or marginalized populations, healthcare workers and other frontline responders, various organizations, and communities. Studies focused on policy responses, the economy, and other social consequences in the U.S. and globally are welcome and encouraged.
Funding notifications will be sent to all applicants no later than April 16.
|Three to five research proposals of up to $3,000 will be funded.|
|In-Part||Online collaboration platform||N/A||Facilitates translation of reserach into commercialisation relating to combating COVID-19 directly (e.g. prophylactic or therapeutic vaccines, anti-viral drugs etc.) or indirectly (e.g. protective equipment, diagnostics etc.)||White papers|
|Allen Institute for AI, Chan Zuckerberg Initiative (CZI), Georgetown U's Center for Security and Emerging Technology (CSET), Microsoft, and the National Library of Medicine (NLM) at the NIH||COVID-19 Open Research Dataset (CORD-19) of scholarly literature about COVID-19, SARS-CoV-2, and the Coronavirus group||N/A||The dataset represents the most extensive machine-readable Coronavirus literature collection available for data and text mining to date, with over 29,000 articles, more than 13,000 of which have full text.|
Now, The White House joins these institutions in issuing a call to action to the Nation’s artificial intelligence experts to develop new text and data mining techniques that can help the science community answer high-priority scientific questions related to COVID-19.
NY State Department of Health
|New policy allows laboratories to begin to use validated COVID-19 diagnostics before the FDA has completed review of the labs’ Emergency Use Authorization (EUA) requests|
and allows other certified labs to test patient samples
|Increase testing kits availability||Integrated DNA Technologies shipped 700,000 tests to commercial, academic and health care laboratories |
Quest Diagnostics and LabCorp started making their own test kits
Many companies, hospitals and other institutions are now racing to develop more tests to diagnose
|Coalition for Epidemic Preparedness Innovations||Funding Vaccines R&D||Up to now, $23.7M to Novavax, Inc., University of Oxford, Curevac Inc., Inovio Pharmaceuticals Inc., Moderna, Inc., and University of Queensland|
|Center for Disaster Philanthropy|
|CDP COVID-19 Response Fund||Support of healthcare workers|
Support of quarantined and vulnerable populations
Support of hygiene promotion activities
|Center for Disaster Philanthropy|
Sharing accurate messaging
Funding preparedness, response and mitigation
United Way of King County
|COVID-19 Response Fund||One-time operating grants distributed to organizations that have deep roots in community and strong experience with disproportionately impacted communities|
FDA, Public Health and Social Services Emergency Fund
|Public funding. Diverse initiatives.||N/A||FDA: support development of medical countermeasures and vaccines, and advanced manufacturing facilities for drugs.|
PH and SSEF: development of countermeasures and vaccines, to expand US manufacturing capabilities, and for the purchase of vaccines, therapeutics, diagnostics.
$61M to FDA
$3.1B to PH and SSEF
$2.2B to Centers for Disease Control and Prevention to support federal, state and local public health agencies
$3B for R&D for vaccines, treatments and diagnostics
$1B for drugs, medical supplies and training
$500M for expanded telehealth services in Medicare
$1B in loan subsidies to help SMEs affected by the outbreak
$1.25B for foreign aid
United Nations Foundation, Swiss Philanthropy Foundation
|COVID-19 Solidarity Response Fund||N/A||Send essential supplies e.g. personal protective equipment to frontline health workers|
Enable countries to track and detect the disease by boosting laboratory capacity through training and equipment
Ensure health workers and communities everywhere have access to the latest science-based information to protect themselves, prevent infection and care for those in need
Accelerate efforts to fast-track the discovery and development of lifesaving vaccines, diagnostics and treatments
|As of March 13, $102M received|
|Genapsys, Foster City|
Chinese Centers for Disease Control, Oxford Finance (financer)
|New portable device for diagnosis||N/A||Testing a new and portable electronic device for DNA sequencing of the novel coronavirus||$75M from Oxford Finance|
|"Rapid test" for COVID||N/A||Simplify the diagnostic test for novel coronavirus, which could soon be used in walk in clinics.|
|WHO||World Health Organization’s (WHO) COVID-19 R&D roadmap||N/A||Drawn up in a two-day meeting of 400 experts from around the world, sets out the gaps in knowledge about the virus and the priorities for future research|
|Innovative Medicines Initiative (IMI)|
|Financing||N/A||Research on diagnostics, therapeutics and prevention||€45M of Horizon 2020 money + €45M from private companies|
|Boston science (funded by China Evergrande Group)||Collaboration among 80 Boston researchers||N/A||Leads: Bruce Walker, director of the Ragon Institute of MGH, MIT, and Harvard with Arlene Sharpe, co-director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital|
Build off a new repository of samples from infected people and community surveillance, materials that can be rapidly shared among scientists
|Startup Health||Cure Disease Moonshot||N/A||Platform to invest in innovators from around the world working on direct or indirect solutions for mitigating, managing, or treating coronavirus or future pandemics||Platform not only dedicated to COVID|
Gasthuisberg hospital at the University of Leuven
|Therapeutics search||N/A||Provide samples of 15,000 drug molecules to the hospital for screening in the search for therapeutics to treat COVID-19 infections.|
|Citadel, Chicago, IL|
|Medical supplies||N/A||Critical medical supplies in Hubei and other regions affected in Cn||7.5M|
|Squirrel AI Learning||Educational courses||N/A||Online K-12 education courses across China free of charge||$72.1 million worth of courses|
|Li Ka Shing Foundation||Medical supplies||N/A||Masks and safety gear for hospitals in HK||250,000 masks to eldery in Hong Kong|
|Gilead||Treatment||N/A||Use of existing Remdesivir, originally developed to treat the Ebola virus|
|Regeneron||Prevention and treatment||N/A||Antibody cocktail against viral proteins identified from its “VelocImmune” mouse technology (same approach it used to develop an Ebola vaccine and drug candidates to treat MERS, Dengue and Zika)|
|Novo Nordisk Foundation||Strengthen Danish R&D for future new viral epidemics||N/A||Strengthen Danish R&D for future new viral epidemics, noting the outbreak of the COVID-19 is not an isolated event i.e. fund interdisciplinary research including surveillance and early detection of viral infections; developing new technologies for preventing or controlling epidemics; and optimising national preparedness to manage new viral diseases, including developing policies and procedures for rapidly testing and approving new treatments, technologies and vaccines.||€2.7M|
|Donations||N/A||- Donation to WHO|
- Rapid Research Funding Opportunity competition through the Canadian Institutes of Health Research
- Swiss National Science Foundation
- UK National Institute for Health Research and the funding agency, UK Research and Innovation
- Germany’s Federal Ministry of Education and Research
|China: $16B investment. $20M to WHO.|
|Canadian-based biotech Cyclica|
Institute of Materia Medica in Beijing, Chinese Academy of Medical Sciences
|Collaboration||N/A||Materia Medica conducts in vitro and in vivo antiviral assessment for molecules proposed by Cyclica|
AI platform to discover antiviral drug candidates for COVID-19 by screening 6,700 FDA-approved drugs and drug candidates with at least Phase I clinical data against the structurally-characterized human proteome with a DL engine, MatchMakerTM, and explore opportunities to design multi-targeted antiviral compounds.
|BioMerieux||Diagnostics||N/A||bioMérieux has finalized the development of the SARS-COV-2 R-GENE® test. This real-time PCR test is clinically validated on one type of respiratory specimen and will be available at the end of March. It is expected to be rapidly CE marked and submitted to the FDA for an EUA (Emergency Use Authorization) as well. |
Two BIOFIRE® tests will be submitted to relevant regulatory authorities in Q2 and Q3 2020 respectively, their launch will follow immediately after regulatory authorization or clearance.